News Releases 2010
The following information was accurate at the time of posting, but may be superseded by subsequent disclosure.
September 7, 2010
Tekmira Receives Clearance from FDA to Initiate TKM-PLK1 Phase 1 Clinical Trial
August 12, 2010
Tekmira Announces Second Quarter 2010 Financial Results
August 10, 2010
Tekmira Conference Call Advisory Second Quarter 2010 Operating Results and Corporate Update
August 5, 2010
Tekmira Files IND Application with U.S. FDA for PLK1 SNALP
July 15, 2010
Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus
July 7, 2010
Tekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01
May 28, 2010
Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi
May 13, 2010
Tekmira Announces First Quarter 2010 Financial Results
May 12, 2010
Tekmira Outlines Plans for a NASDAQ Listing
May 11, 2010
Tekmira Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update
May 10, 2010
Tekmira Announces Multi-Year Agreement with Bristol-Myers Squibb
March 23, 2010
Tekmira Announces Advances in Identifying and Preventing siRNA-Mediated Immune Stimulation
March 17, 2010
Tekmira Provides Corporate Update and Reports 2009 Audited Results
March 16, 2010
Tekmira and Pfizer Initiate New Research Collaboration
March 15, 2010
Tekmira Conference Call Advisory 2009 Audited Results and Corporate Update
February 23, 2010
Tekmira Presents ApoB SNALP Data at AsiaTIDES RNAi Scientific Conference
February 9, 2010
Tekmira Announces 2010 Milestones
February 4, 2010
Tekmira to Present at 12th Annual BIO CEO & Investor Conference
January 28, 2010
Tekmira Appoints New Chairman and Two New Independent Directors
January 19, 2010
Tekmira Makes Significant Improvements in the Potency of its Leading RNAi Delivery Platform
January 7, 2010
Tekmira Completes ApoB SNALP Phase 1 Clinical Trial
